PRESS RELEASE published on 06/05/2025 at 12:30, 9 months 17 days ago Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS Immunic completes enrollment for Phase 3 ENSURE trials in Relapsing MS and presents positive Phase 2 CALLIPER trial data in Progressive MS, showcasing vidofludimus calcium's potential. Top-line data in 2026 Immunic Vidofludimus Calcium Phase 3 ENSURE Trials Phase 2 CALLIPER Trial Relapsing MS
BRIEF published on 06/02/2025 at 12:35, 9 months 20 days ago Immunic to Attend Key Conferences in June Biotechnology Conférences Immunic Vidofludimus Calcium Investor Meetings
BRIEF published on 06/02/2025 at 12:35, 9 months 20 days ago Immunic participera à des conférences clés en juin Biotechnologie Conférences Réunions D'investisseurs Immunique Vidofludimus Calcique
PRESS RELEASE published on 06/02/2025 at 12:30, 9 months 20 days ago Immunic to Participate in Investor, Scientific and Industry Conferences in June Immunic, Inc. to participate in multiple investor, scientific, and industry conferences in June 2025, presenting research and clinical pipeline updates Biotechnology Conférences Scientific Research Immunic Inc. Clinical Pipeline
BRIEF published on 05/02/2025 at 12:35, 10 months 20 days ago Immunic to Engage in Key Conferences in May Clinical Trials Conférences Multiple Sclerosis Immunic Celiac Disease
BRIEF published on 05/02/2025 at 12:35, 10 months 20 days ago Immunic participera à des conférences clés en mai Conférences Essais Cliniques Sclérose En Plaques Immunique Maladie Cœliaque
PRESS RELEASE published on 05/02/2025 at 12:30, 10 months 20 days ago Immunic to Participate in Scientific and Industry Conferences in May Immunic to participate in scientific and industry conferences in May, including DDW and CMSC Annual Meeting 2025, presenting on IMU-856 and vidofludimus calcium for autoimmune diseases Immunic Autoimmune Diseases Industry Conferences Scientific Conferences IMU-856
BRIEF published on 04/30/2025 at 13:35, 10 months 22 days ago Immunic Reports Phase 2 CALLIPER Trial Results for Vidofludimus Calcium Multiple Sclerosis Vidofludimus Calcium Immunic AG Clinical Trial Results Phase 2 CALLIPER Trial
BRIEF published on 04/30/2025 at 13:35, 10 months 22 days ago Immunic annonce les résultats de l'essai de phase 2 CALLIPER pour le vidofludimus calcique Sclérose En Plaques Immunic AG Résultats Des Essais Cliniques Vidofludimus Calcique Essai CALLIPER De Phase 2
PRESS RELEASE published on 04/30/2025 at 13:30, 10 months 22 days ago Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial Immunic announces positive results from Phase 2 CALLIPER trial showing 30% reduced risk of disability worsening in Primary Progressive Multiple Sclerosis patients with vidofludimus calcium. Webcast scheduled for April 30 Multiple Sclerosis Immunic Vidofludimus Calcium Phase 2 CALLIPER Trial
Published on 03/20/2026 at 13:30, 2 days 8 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 9 hours ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/22/2026 at 12:23, 9 hours 35 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 23 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 2 days ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 2 days ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 19:00, 2 days 2 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 2 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 3 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 3 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA